FDA approves EPIDIOLEX, an oral cannabidiol solution to treat seizures associated with Tuberous Sclerosis Complex (TSC) in patients one year of age and older. Along with this new indication, the age range has been expanded to include patients one year of age and older who experience seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome. Officials anticipate that the label expansion further demonstrates that the FDA process can continue to enable broader patient access to appropriately test regulatory approved cannabinoid medicines.
– Published Ncv Newswire, New Cannabis Ventures, 08/03/2020 7:48:37 AM
Open article: https://www.newcannabisventures.com/fda-expands-gw-pharmas-epidiolex-label/